US Stock Movement: Tempus AI surged on October 20 with AI pre-screening for non-small cell lung cancer and biomarker detection
Bitget异动解读2026/10/20 16:45Tempus AI Soars on October 20: Analysis
Keywords: AI pre-screening for non-small cell lung cancer, biomarker testing
On October 19, Tempus announced results from an AI-assisted pre-screening study for advanced non-small cell lung cancer: analyzing 60,459 cases and involving 12 types of biomarkers, with all sensitivities exceeding 80% using standard H&E pathological images, and several surpassing 90%. The study results will be presented at the 2026 European Society for Medical Oncology Congress.
(Disclaimer: This content is generated by AI technology summarizing public information and is for reference only. It does not constitute investment advice.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Amgen (AMGN.US) and AstraZeneca (AZN.US) combination therapy extends small cell lung cancer survival by eight months, reduces risk of death by 58%
Researchers combined Amgen's Imdelltra with AstraZeneca's Imfinzi and found that for patients with aggressive lung cancer whose tumors had already spread, this combination extended survival by about eight months compared to Imfinzi monotherapy. Small cell lung cancer is one of the cancer types with the worst prognosis.
Crypto prices
More
